United States: Issue 104: Departments Issue FAQs On The Mental Health Parity And Addiction Equity Act And Request Comments On Tobacco Cessation Products

This is the one hundred and fourth issue in our series of alerts for employers on selected topics on health care reform. (Click here to access our general Summary of Health Care Reform and other issues in this series.) This series of Health Care Reform Management Alerts is designed to provide an in-depth analysis of certain aspects of health care reform and how it will impact your employer-sponsored plans.

On October 26, 2016, the Departments of Health and Human Services, Labor and Treasury (the Departments) published issue 34 of their series of FAQs on the Affordable Care Act, found here. The FAQs discuss the Mental Health Parity and Addiction Equity Act and seek input for future guidance on tobacco cessation coverage as part of preventive care services.

I. Preventive Care: Request for Comments on Tobacco Cessation Coverage

Background: The Departments have issued several pieces of guidance on the Affordable Care Act's requirement to cover preventive care. See our alerts here, here, and here. Non-grandfathered plans must cover tobacco use counseling and intervention as preventive care.

Safe Harbor: What is my plan required to cover in terms of tobacco cessation? In prior FAQs, the Departments said that a plan would be in compliance with this requirement if, for example, the plan covers without cost sharing or prior authorization: (1) screening for tobacco use; and (2) for those who use tobacco products, at least two tobacco cessation attempts per year. For this purpose, covering a cessation attempt includes coverage for: (i) four tobacco cessation counseling sessions of at least 10 minutes each (including telephone counseling, group counseling and/or individual counseling); and (ii) all Food and Drug Administration (FDA)-approved tobacco cessation medications (including both prescription and over-the-counter medications) for a 90-day treatment regimen when prescribed by a health care provider. Later the United States Preventive Services Task Force stated that pharmacotherapy and behavioral interventions both are effective and recommended; combinations of interventions are most effective, and all should be offered.

FAQs: Before providing additional guidance on what items and services must be provided without cost sharing, the Departments seek comments on whether the plan may use medical management techniques to determine which categories of FDA-approved pharmacotherapy interventions must be covered without cost sharing, and whether plans can use medical management techniques to, for example, limit the number of quit attempts per year or limit the types of behavioral interventions that are covered without cost sharing.

II. Mental Health Parity and Addiction Equity Act

Background: As discussed in our February 6, 2014 Management Alert (found here) on the Mental Health Parity and Addiction Equity Act (MHPAEA), a group health plan or policy that includes medical and surgical benefits and mental health and substance use disorder ("mental health") benefits cannot impose financial requirements (e.g., deductibles and co-payments) or quantitative treatment limitations (e.g., number of visits or days of coverage) on mental health benefits that are more restrictive than the predominant financial requirements or treatment limitations that apply to substantially all medical and surgical benefits (this is referred to as the "substantially all/predominant test"). Additionally, the standards for nonquantitative treatment limitation (NQTL) for mental health benefits in any classification must be comparable to, and no more stringent than, the standards used in applying the limitation for medical and surgical benefits in the same classification.

FAQs: The Departments seek comments on issuing model forms that could be used by participants to request information on NQTLs and introduce a Parity Consumer Web Portal that individuals can use to connect to the appropriate agency for help in obtaining documents or information:www.hhs.gov/mental-health-and-addiction-insurnace-help.

A. Financial Requirements and Quantitative Treatment Limitations: Use of the Plan's Claims Data in Performing the Substantially All/Predominant Test

Background: The substantially all/predominant test is a quantitative analysis and is run using the dollar amount of all plan payments for medical and surgical benefits in the classification expected to be paid under the plan for the plan year.

The MHPAEA regulations established six classifications of benefits:

  • in-patient/in-network,
  • in-patient/out-of-network,
  • out-patient/in-network,
  • out-patient/out-of-network,
  • emergency care, and
  • pharmacy benefits.

Additionally, plans can subdivide outpatient benefits into office visits, and all other outpatient items and services.

FAQs: The FAQs clarify that a plan generally should use its own claims data to perform the analysis. However, the Departments also acknowledge there could be circumstances where the plan's data would not give a fair estimation of the payments to be made. For example, using the plan's data could be unreasonable if there is insufficient data, the plan significantly changed its benefit package, the plan experienced a significant workforce change that would impact claims costs, or the plan design is new. In that case, the plan should use other claims data to make a reasonable projection to conduct actuarially-appropriate analyses. For example, the plan could use data from similarly-structured plans with similar demographics. The assumptions used in choosing a data set and making projections should be documented and, to the extent possible, the claims data should be customized to reflect the plan's characteristics. Any determination that the plan's claims data is unreasonable should be made by an actuary who is subject to (and meets) the qualification standards for the issuance of a statement of actuarial opinion in regard to health plans in the United States, and who has the necessary education and experience to provide the actuarial opinion.

How often does our plan have to perform the substantially all/predominant test? It depends on the facts and circumstances. We do know the plan is not required to perform the test each year unless there is a change in plan benefit design, cost-sharing structure, or utilization that would affect a financial requirement or treatment limitation within a classification (or sub-classification).

B. Nonquantitative Treatment Limitations (NQTLs): Plan Designs that Could Raise Red Flags

Background: A plan may not impose an NQTL with respect to mental health benefits in any classification unless, under the terms of the plan as written and in operation, the NQTL is comparable to and not applied more stringently than NQTLs for medical and surgical benefits in the same classification.

What are some examples of NQTLs?

  • Medical management standards limiting or excluding benefits based on medical necessity or medical appropriateness, or based on whether the treatment is experimental or investigative;
  • Formulary design for prescription drugs;
  • For plans with multiple network tiers (such as preferred providers and participating providers), network tier design;
  • Standards for provider admission to participate in a network, including reimbursement rates;
  • Plan methods for determining usual, customary, and reasonable charges;
  • Refusal to pay for higher-cost therapies until it can be shown that a lower-cost therapy is not effective (also known as fail-first policies or step therapy protocols);
  • Exclusions based on failure to complete a course of treatment; and

Restrictions based on geographic location, facility type, provider specialty, and other criteria that limit the scope or duration of benefits for services provided under the plan or coverage.

FAQs: The FAQs provide a number of examples of NQTLs applied inconsistently between mental health and medical and surgical conditions that would violate the MHPAEA, including the following:

  • A process for obtaining authorization for inpatient, in-network facilities requiring the participant to obtain an in-person exam for coverage of a mental health condition but allowing a telephone authorization for medical and surgical benefits.
  • A requirement that the participant first enroll in an intensive outpatient program before authorizing coverage for inpatient treatment for a substance use disorder where no such program is available in the participant's geographic area. Under the facts provided, a similar requirement exists for medical and surgical benefits. However, the FAQs state that if (i) a fail-first requirement that applies to mental health benefits includes a condition that an individual cannot reasonably satisfy (in this case, first attempting an intensive outpatient program where there are no such programs available), and (ii) the lack of access to programs necessary to satisfy the requirement exists only with respect to mental health benefits, then the fail-first requirement is operationally applied more stringently with respect to mental health than medical and surgical benefits. This guidance on situations involving lack of access applies for plan years beginning on or after March 1, 2017.
  • A requirement that the participant obtain authorization from the plan that buprenorphine is medically necessary for the treatment of his or her opioid use disorder due to safety risks. Under the facts provided, similar safety risks exist for prescription drugs to treat medical and surgical conditions but the plan does not require prior authorization on those drugs.
  • A requirement that the participant meet a non-pharmacological fail-first requirement (for example, trying counseling alone) before the plan will authorize coverage for buprenorphine to treat an opioid use disorder. Under the facts provided, similar fail-first requirements could be imposed on prescription drugs covered by the plan for medical and surgical conditions, but are not.
  • Stating that the plan follows nationally-recognized treatment guidelines for setting prior authorization requirements for prescription drugs, but deviates from such guidelines for drugs use for an opioid use disorder. The FAQs note that plans can use Pharmacy and Therapeutics (P&T) committees in deciding how to cover prescription drugs and evaluating whether to follow or deviate from nationally-recognized treatment guidelines for setting the prior authorization requirements but these processes must comply with MHPAEA's NQTL standard in operation.
  • An exclusion of court-ordered treatment for substance use disorders when the plan does not exclude court-ordered treatment for medical and surgical conditions.


Issue 34 of the Departments' FAQs provides a helpful summary of the requirement to provide tobacco cessation as part of plan's preventive care offerings and practical examples of plan designs and operations that could be red flags as to an MHPAEA violation. In light of the report of the White House Mental Health and Substance Use Disorder Parity Task Force (issued simultaneous with the FAQs) recommending an expansion of MHPAEA compliance audits, and the passage of the 21st Century Cures Act which clarifies the Departments' authority to audit a health plan that has been found to have violated existing mental health parity laws five times (see our Alert here), employers should ensure that benefits provided for mental health and substance use disorder are at least as generous as medical and surgical benefits.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.